Reichstag building in Berlin, Photo by Jürgen Matern

The International Society on Thrombosis and Haemostasis (ISTH) 2017 Congress took place July 7-13 in Berlin, Germany.

Product can reduce, prevent bleeding in kids with FXD



Vials and a syringe
Results of a phase 3 study suggest prophylaxis with plasma-derived factor X (pdFX, Coagadex®) prevents or reduces bleeding episodes in children with moderate to severe hereditary factor X deficiency (FXD). pdFX was well tolerated in this study as well, with no treatment-related adverse events (AEs) reported. “For the first... [Read Article]

Death is most frequent major adverse outcome after VTE



Patient takes anticoagulant
after knee surgery
Photo courtesy of
Boehringer Ingelheim
Data from the GARFIELD-VTE registry showed that, in the first 6 months after a patient was diagnosed with venous thromboembolism (VTE), death was the most frequent major adverse outcome. More than half of the deaths were related to cancer, with small... [Read Article]

RNAi therapeutic reduces ABR in hemophilia A and B



RNA
Image by AJ Cann
Researchers have reported positive results from an ongoing phase 2 trial of fitusiran in patients with hemophilia A or B, with or without inhibitors. Once-monthly treatment with fitusiran reduced the median annualized bleeding rate (ABR) from 20 to 1 in all patients. In patients with inhibitors, the ABR... [Read Article]

Gene therapy maintains normal FVIII levels long-term



DNA helix
Image by Spencer Phillips
New research suggests the investigational gene therapy BMN 270 can allow patients with severe hemophilia A to maintain normal factor VIII (FVIII) levels for over a year. In a phase 1/2 study, patients who received the highest dose of BMN 270 had median and mean FVIII levels... [Read Article]

Idarucizumab reverses effects of dabigatran in emergencies



Team performing surgery
Photo by Piotr Bodze
Final results from the RE-VERSE AD trial suggest idarucizumab can reverse the anticoagulant effect of dabigatran etexilate mesylate in emergency situations. Patients who required dabigatran reversal because they needed urgent surgery were able to have their procedure a median of 1.6 hours from idarucizumab administration. In... [Read Article]

Antibody reduces bleeding in hemophilia A patients with inhibitors



Monoclonal antibodies
Photo by Linda Bartlett
Emicizumab can reduce bleeding in adults and adolescents with hemophilia A and inhibitors to factor VIII, according to a phase 3 trial. In the HAVEN 1 trial, prophylaxis with emicizumab reduced the treated bleed rate by 87% when compared to no prophylaxis. Emicizumab reduced the treated... [Read Article]